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ABSTRACT 
Pituitary adenylate cyclase-activating polypeptide (PACAP) acts on cortical precursor 
cells to trigger glial fibrillary acidic protein (GFAP) gene expression and astrocyte 
differentiation by stimulation of intracellular cAMP production. Here, we show that as 
expected, PACAP activates cAMP-dependent protein kinase A. However, inhibition of 
protein kinase A does not prevent PACAP-induced GFAP gene expression or 
astrocytogenesis. PACAP also activates the small GTPases Rap1 and Ras, but either 
activation of Rap1 alone by selective stimulation of the guanine nucleotide exchange 
factor Epac, or expression of a constitutively active form of Ras, do not induce GFAP 
gene expression. Ras is activated by PACAP in a cAMP-dependent manner, and 
inhibition of Ras and/or Rap1 decreases PACAP-induced GFAP promoter stimulation. 
Thus, cAMP-dependent PACAP-induced GFAP expression during astrocytogenesis 
involves the coordinated activation of both Ras and Rap1, but activation of either one of 
them in isolation is not sufficient to trigger this response. 
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INTRODUCTION 
During development of the central nervous system, the sequential generation of 
the different cell types destined to populate the adult brain depends, in part, on the type 
of extracellular signals to which neural precursors are exposed (Sauvageot and Stiles, 
2002). Cortical astrocytes differentiate from progenitor cells exposed to cytokines of the 
interleukin-6 family, such as ciliary neurotrophic factor (CNTF), leukemia inhibitory 
factor (LIF) or cardiotrophin-1, or to bone morphogenetic proteins (BMP) (Barnabé-
Heider et al., 2005; Bonni et al., 1997; Gross et al., 1996; Ochiai et al., 2001; Rajan and 
McKay, 1998). The physiologic relevance of these findings is supported by studies 
showing that genetically engineered mice lacking one of the neurotrophic cytokines or 
their receptors exhibit a reduced number of astrocytes (Barnabé-Heider et al., 2005; 
Bugga et al., 1998; Koblar et al., 1998; Nakashima et al., 1999a), whereas the opposite 
is observed in the brains of mice overexpressing BMP (Gomes et al., 2003). 
Intracellular signaling systems triggered by neurotrophic cytokines and BMP, leading to 
the stimulation of GFAP gene transcription in differentiating astrocytes, involve the 
activation of STAT and Smad proteins, respectively (Bonni et al., 1997; He et al., 2005; 
Nakashima et al., 1999b; Rajan and McKay, 1998). 
 Previous studies carried out in our laboratory indicate that pituitary adenylate 
cyclase-activating polypeptide (PACAP), a member of the vasoactive intestinal peptide 
(VIP)/secretin/glucagon family, provides an additional signal for the generation of 
astrocytes from neural precursor cells (Cebolla and Vallejo, 2006; Vallejo and Vallejo, 
2002). PACAP promotes astrocyte differentiation by acting on specific PAC1 receptors 
present in cortical precursor cells. These receptors use the cAMP-dependent pathway as 
a major intracellular signaling mechanism of peptide activation (Spengler et al., 1993), 
and therefore exposure of cortical precursor cells to PACAP results in increased 
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intracellular levels of cAMP (Vallejo and Vallejo, 2002). In addition, we found that the 
cAMP analog 8Br-cAMP is able to trigger astrocyte differentiation from cortical 
precursors (McManus et al., 1999), and that the astrocytogenic effect of PACAP can be 
blocked by a specific cAMP antagonist (Vallejo and Vallejo, 2002), thus supporting the 
notion that PACAP induces cortical precursor cell differentiation into astrocytes by 
activating a cAMP-dependent signaling pathway. However, the mechanisms by which 
cAMP triggers this response remain unknown. 
 It is known that cAMP can activate at least three different signaling pathways 
within cells. The first one to be characterized and the most extensively studied relies on 
the activation of protein kinase A (PKA), which then phosphorylates different 
substrates, including transcription factors such as CREB. Independently, cAMP can 
stimulate the guanine nucleotide exchange protein Epac (also known as cAMP-GEF), 
which then activates the GTPase Rap-1 (Bos, 2003). Finally, a third pathway has been 
identified in which the cAMP effector is another guanine nucleotide exchange protein 
called CNrasGEF, which activates Ras directly (Pham et al., 2000). In the present study, 
we have sought to determine the relative contributions of each one of these pathways to 
the stimulation of GFAP gene transcription during the astrocytogenic effect of PACAP 
in cortical precursor cells. 
 
RESULTS 
Astrocyte differentiation and stimulation of GFAP gene expression by PACAP do 
not require protein kinase A activity. We have previously determined that treatment 
of primary cortical precursor cells obtained from the brains of rat fetuses of 17 days of 
gestational age (E17) with PACAP or with the cAMP analog 8Br-cAMP results in 
astrocyte differentiation and stimulates GFAP expression (Cebolla and Vallejo, 2006; 
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McManus et al., 1999; Vallejo and Vallejo, 2002). To confirm those findings we carried 
out immunofluorescence experiments and determined that fetal primary cortical cells 
proliferating in the presence of basic fibroblast growth factor (bFGF) express the neural 
precursor marker nestin, but not the glial markers GFAP or S100β, nor the neuronal 
marker Tuj1 (Fig. 1A). When cells were treated with PACAP, nestin expression was 
downregulated and expression of the astroglial markers GFAP and S100β was induced 
(Fig. 1B). Exposure to PACAP did not induce expression of Tuj1 (Fig. 1B). However, 
when cells were treated with BDNF instead of PACAP, nestin expression was 
downregulated and Tuj1 expression was induced (Fig. 1C). Since coexpression of 
GFAP and S100β is a feature of mature astrocytes (Raponi et al, 2007), these results 
confirm our previous data and show that PACAP induces astrocyte differentiation from 
cortical precursor cells prepared from the brains of rat fetuses. 
 To monitor transcriptional responses of the GFAP gene promoter triggered by 
PACAP or 8Br-cAMP, we used transient transfections with GFAP-A7Luc, a GFAP-
luciferase reporter plasmid that we have previously used to identify and characterize 
promoter elements in the GFAP gene (Cebolla and Vallejo, 2006). We found that the 
luciferase activity elicited by PACAP is mimicked by 8Br-cAMP (Fig. 2A), supporting 
the notion that cAMP production by PACAP is sufficient to stimulate transcription from 
the GFAP promoter. Thus, we initially asked whether activation of PKA is required for 
PACAP-induced transcriptional transactivation of the GFAP promoter. To this end, we 
carried out transfections in primary cortical cells that had been pretreated with the PKA-
specific inhibitor H89. We found that H89 does not inhibit luciferase activity in 
response to treatment of cells with PACAP (Fig. 2B).  
 Although cAMP is synthesized in cells upon activation of PACAP receptors, it is 
known that PACAP can induce the activation of different intracellular signaling systems 
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(Grimaldi and Cavalaro, 1999; Lu et al., 1998; Nicot and DiCicco-Bloom, 2001; 
Spengler et al., 1993; Vallejo and Vallejo, 2002). Therefore, in view of these results, we 
considered the possibility that PKA is not activated in neural precursor cells exposed to 
PACAP. However, we ruled out this possibility, because we observed that treatment of 
cells with PACAP readily resulted in the phosphorylation of CREB (Fig. 2C), a well 
known target of PKA, and this phosphorylation was inhibited by pretreatment with H89 
(Fig. 2D). 
 We found also that pretreatment with H89 did not prevent stimulation of 
endogenous GFAP expression (Fig. 2E) and did not block astrocyte differentiation 
elicited by PACAP in primary cortical precursor cells (Fig. 2F). Thus, we conclude 
from these experiments that exposure of cortical precursor cells to PACAP results in 
activation of PKA, but PKA is not involved in the transcriptional transactivation of the 
GFAP promoter during astrocyte differentiation. 
 Since cAMP activity is required for astrocyte differentiation induced by PACAP 
(Vallejo and Vallejo, 2002), we argued that cAMP could activate additional signaling 
pathways different from PKA, and we turned our attention to investigate the possible 
involvement of the Epac-Rap1 and/or the CNrasGEF/Ras pathways. 
 
Involvement of Epac-Rap1. To investigate whether PACAP-induced GFAP gene 
expression could be due to the specific activation of Epac-Rap1, we first determined 
whether treatment of primary cortical precursors with PACAP results in activation of 
Rap1. Activated Rap1 (Rap1-GTP) was assayed using a glutathione S-transferase (GST) 
pull-down assay with a fusion protein composed of GST and the Rap1 binding domain 
of RalGDS (GST-RalGDS-RBD), which specifically binds the active, GTP-bound form 
of Rap1, followed by western immunoblotting with a Rap1-specific antibody (de Rooij 
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and Bos, 1997; Zwartkruis et al., 1998). We observed that treatment of primary cortical 
precursor cells with PACAP results in the activation of Rap1. The onset of this response 
is relatively slow, reaching maximum levels 15 min after exposure of cells to PACAP, 
and persisting for at least 30 minutes (Fig. 3A). As a positive control, we observed that 
Rap1 is activated by exposure for 15 minutes to 8CPT-2-O-Me-cAMP (Fig. 3A), a 
cAMP analog that is a selective activator of Epac (Enserink et al., 2002). 
 In addition, we tested whether the blockade of the PACAP-induced activation of 
the Epac-Rap1 pathway would affect the stimulation of GFAP promoter activity. For 
this purpose, we cotransfected primary cortical precursor cells with the reporter plasmid 
GFAP-A7Luc and an expression vector encoding Rap1N17, a dominant negative 
mutant of the Epac effector Rap1 (Vossler et al., 1997). We observed that in the 
presence of increasing amounts of Rap1N17, the stimulatory effect of PACAP on GFAP 
promoter activity decreased (Fig. 3B). In contrast, Rap1N17 did not prevent the 
stimulation of the GFAP promoter induced by CNTF (Fig. 3C), supporting the notion 
that the effect of Rap1N17 is not due to toxicity and that the induction of GFAP 
promoter activity by PACAP in neural precursors involves the specific activation of the 
Epac-Rap1 pathway. 
 Based on these results, it could be expected that stimulation of Epac in cortical 
precursor cells should trigger astrocyte differentiation and induce GFAP expression by 
stimulating transcriptional activity of the GFAP promoter. To test this notion, we 
transfected primary cortical precursors with the reporter plasmid GFAP-A7Luc, and 
treated them with the Epac-specific agonist 8CPT-2-O-Me-cAMP. We found that this 
treatment did not increase basal luciferase activity, indicating that this compound is not 
able to mimic the activity of PACAP or 8Br-cAMP on the GFAP promoter (Fig. 4A). In 
addition, in contrast with what we observed in the case of PACAP or 8Br-cAMP, 
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exposure of primary cortical precursor cells to 8CPT-2-O-Me-cAMP did not induce 
endogenous GFAP expression or astrocyte differentiation, as assessed by western 
immunoblot and immunocytochemistry, respectively (Fig. 4B and C). 
 Taken together, these experiments suggest that activation of the Epac-Rap1 
pathway is involved in the response to PACAP but it is not sufficient to stimulate GFAP 
promoter activity on its own. Since inhibition of intracellular signaling by a cAMP-
specific antagonist blocks astrocyte differentiation induced by PACAP (Vallejo and 
Vallejo, 2002), we sought to investigate whether an additional cAMP-dependent 
pathway could be activated. For this reason, we studied the possible involvement of 
Ras, which can be activated via stimulation of the cAMP-dependent exchange factor 
CNrasGEF (Pham et al., 2000). 
 
Involvement of Ras. To test whether PACAP can activate Ras in primary cortical 
precursor cells, we used a GST pull-down assay with a fusion protein composed of GST 
and the Ras-binding domain of Raf1 (GST-Raf1-RBD), which specifically binds the 
active, GTP-bound form of Ras, followed by western immunoblotting with a Ras-
specific antibody (Taylor and Shalloway, 1996). We found that PACAP transiently 
activates Ras within 5 minutes of treatment, and by 15 minutes the levels of GTP-bound 
Ras had practically returned to basal levels (Fig. 5A). 
 To test whether Ras activation is related to the effect of PACAP on GFAP gene 
expression, we cotransfected primary cortical precursor cells with GFAP-A7Luc and an 
expression vector encoding RasN17, a dominant negative mutant of Ras (Matallanas et 
al., 2003). Expression of RasN17 resulted in a marked, although incomplete inhibition 
of the luciferase activity induced by PACAP, but did not affect luciferase activity 
induced by CNTF (Fig. 5B and C), indicating that the effect of RasN17 is not due to 
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toxicity. Thus, the activation of Ras on its own appears to be important for the 
stimulation of the GFAP gene promoter triggered by PACAP. Then, we sought to 
explore whether activation of Ras is sufficient to stimulate transcription from the GFAP 
promoter using RasV12, a constitutively active mutant of Ras (Delgado et al., 2000). 
We observed that cotransfections of primary cortical precursors with the GFAP-A7Luc 
reporter and with increasing amounts of an expression vector encoding RasV12 did not 
alter luciferase activity significantly (Fig. 5D), indicating that activation of Ras is not 
sufficient to stimulate GFAP gene expression. 
 Ras can be activated by cAMP via stimulation of the nucleotide exchange factor 
CNrasGEF (Pham et al., 2000). Because no cAMP analogs that act specifically and 
selectively as CNrasGEF agonists have been developed, we tested the involvement of 
cAMP on the PACAP-induced activation of Ras indirectly. We have observed 
previously that the ability of PACAP to induce astrocyte differentiation from primary 
cortical precursors can be mimicked by 8Br-cAMP, and can be blocked by the cAMP 
antagonist Rp-cAMPS (McManus et al., 1999; Vallejo and Vallejo, 2002). In agreement 
with these findings, we observed that pretreatment of cells with Rp-cAMPS inhibits the 
activation of Ras induced by PACAP (Fig. 6A). In addition, in transfected cells, 
stimulation of GFAP-A7Luc activity elicited by treatment of cells with 8Br-cAMP was 
reduced in the presence of the dominant negative inhibitor RasN17 (Fig. 6B). 
 The experiments carried out using either the Rap1 inhibitor Rap1N17 or the Ras 
inhibitor RasN17 show that inhibition of the transcriptional activity of the GFAP 
promoter stimulated by PACAP is not complete. Therefore, we tested the effects of the 
two negative dominant inhibitors together. In agreement with our previous results, 
PACAP-induced GFAP-A7Luc activity in transfected primary cortical precursor cells 
was reduced by about 40% in the presence of the Rap1 inhibitor, and by almost 50% in 
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the presence of the Ras inhibitor (Fig. 7A). When both inhibitors were present together, 
PACAP-, but not CNTF-induced GFAP promoter activity was inhibited by more than 
80% (Fig. 7A and B). In addition, we observed that knockdown of both Ras and Rap1 
by RNA interference prevented the stimulation of endogenous GFAP expression 
induced by PACAP without affecting the stimulation induced by CNTF (Fig. 7C). 
 All of the above experiments indicate that activation of either Ras or Rap1 is not 
sufficient to stimulate the GFAP gene promoter, although both appear to be necessary 
for stimulation. This suggests that the expression of GFAP in neural precursor cells 
requires the coordinated activation of both signaling pathways. To test this notion, we 
cotransfected GFAP-A7Luc with the expression vector encoding RasV12 to stimulate 
the Ras-dependent pathway constitutively, and then treated the cells with 8CPT-2-O-
Me-cAMP to stimulate the Epac-Rap1-dependent pathway. These experiments showed 
that 8CPT-2-O-Me-cAMP only activated luciferase activity when was RasV12 present, 
even though RasV12 had no effect on its own (Fig. 7D). Therefore, these experiments 
indicate that GFAP promoter stimulation require the concomitant activation of both 
Epac-Rap1- and Ras-dependent signaling pathways. 
 
DISCUSSION 
 Our previous work indicates that induction of astrocytogenesis and stimulation 
of GFAP gene expression by PACAP are due to activation of specific PAC1 type 
receptors expressed on cortical precursor cells and depend on the activation of signaling 
pathways that require cAMP (Vallejo and Vallejo, 2002). In the present study we show 
that stimulation of GFAP gene expression by PACAP in cortical precursors is 
associated to activation of the small GTPases Rap1 and Ras. Interestingly, isolated 
stimulation of Epac-Rap1 with a specific cAMP analog or constitutive activation of Ras 
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alone are not sufficient to activate transcription from the GFAP promoter. Instead, we 
found that this response requires the coordinated activation of both signaling pathways. 
This is not entirely surprising in view of the number and complexity of interactions that 
mediate crosstalk between the different cAMP-dependent signaling cascades within 
cells (Stork and Schmitt, 2002). In addition, our data are in agreement with the observed 
lack of effects of a constitutively active isoform of Rap1 expressed in differentiating 
astrocytes of transgenic mice on astrocyte differentiation (Apicelli et al., 2003). 
 We observed that the activation of Rap1 is delayed and it is apparently weaker 
relative to that of Ras. Thus, it could be possible that activation of Rap1 requires 
previous activation of Ras, as has been shown to be the case in different cell types (Li et 
al., 2006). However, it is unlikely that activation of Rap1 in cortical precursors depends 
entirely on activation of Ras, because partial GFAP promoter stimulation is still 
observed in the presence of the dominant negative inhibitor RasN17. 
 Activation of Rap1 and/or Ras by PACAP has been shown in different cell 
types, including neuronal cells and astrocytes (Bouschet et al., 2003; Dasgupta et al., 
2003; Obara et al., 2007; Romano et al., 2003). In pituitary cells, PACAP-induced 
transactivation of the prolactin gene promoter is also accompanied of the activation of 
Rap1 and Ras (Romano et al., 2003). However, in this case the activations of these 
signaling pathways have antagonic effects: whereas Rap1 stimulates transcription, Ras 
inhibits prolactin gene promoter activity. In PC12 and in cerebellar granule cells 
stimulation of ERKs by PACAP requires that both Rap1 and Ras are activated 
(Bouschet et al., 2003; Obara et al., 2007). Interestingly, the activation of these small 
GTPases by PACAP in cerebellar cells requires the activation of PKA by cAMP (Obara 
et al., 2007). 
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 We found that PACAP is able to activate PKA in cortical precursor cells, and 
that this activation is responsible for phosphorylation of CREB. Studies carried out in 
pituitary cells indicate that PACAP, acting on PAC1-type receptors, induces 
transcription of the gonadotropin-releasing hormone receptor gene by stimulating 
promoter activity via phosphorylation of CREB by cAMP-dependent PKA (Pincas et 
al., 2001). However, in cortical precursor cells we found that the stimulation of 
promoter activity of the GFAP gene is independent of the activation of PKA, because 
PACAP induces GFAP expression and triggers astrocyte differentiation even in the 
presence of a PKA inhibitor. Since inhibition of either Rap1 or Ras results in decreased 
PACAP-induced GFAP promoter activity, it follows that PKA is not required for the 
activation of Rap1 or Ras in these cells. In addition, the observation that PKA activation 
and CREB phosphorylation do not participate in PACAP-induced GFAP gene 
expression is consistent with the observation that the region of the GFAP promoter that 
mediates cAMP-dependent transactivation does not contain any sequence corresponding 
to a typical cAMP-response element for binding of CREB-like proteins (BC and MV, 
unpublished). A detailed characterization of the GFAP promoter region that confers 
responsiveness to PACAP/cAMP has been carried out in our laboratory and will be 
reported elsewhere. 
 In mature astrocytes, PACAP/cAMP signaling leads to activation of Rap1, but as 
a consequence Ras is inhibited (Apicelli et al., 2003; Dasgupta et al., 2003; Dugan et 
al., 1999), in agreement with previous studies showing that inhibition of the Ras/Raf1 
pathway by Rap1 is dependent on cAMP activation of PKA (Altschuler et al., 1995; 
Schmitt and Stork, 2001). In contrast, in glial progenitors we observed that both Rap1 
and Ras are activated by PACAP. It is known that PACAP acts on PAC1 receptors 
expressed in cortical cells, but it exerts different actions depending on their 
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developmental stage. Thus, before birth PACAP promotes neuronal differentiation from 
early neural precursors (Suh et al., 2001) and astrogliogenesis from late precursors 
(Nishimoto et al., 2007; Vallejo and Vallejo, 2002), whereas postanally, PACAP 
regulates the growth and differentiation of oligodendrocyte progenitors (Lee et al., 
2001). Therefore the signaling mechanisms on which PACAP acts during cortical 
development appear to differ in different cell lineages and to be developmentally 
regulated. This developmental regulation could be due to the differential expression of 
effector proteins such as B-Raf, activated by Rap1, that is not expressed in mature 
astrocytes (Dugan et al., 1999). In addition, the generation of different PAC1 receptor 
splice variants in cortical precursors (Vallejo and Vallejo, 2002) could be responsible 
for the coupling to different signaling pathways. 
 It is known that astrocytes derive sequentially from the same precursor cells that 
first generate neurons (Barnabé-Heider et al., 2005; Miller and Gautier, 2007; Qian et 
al., 2000). We found that PACAP does not induce neuronal differentiation from E17 
precursors, although earlier reports suggest that PACAP can induce neuronal 
differentiation from E13.5 precursor cells (Lu and DiCicco-Bloom, 1997). In turn, we 
have observed that PACAP is unable to induce astrocyte differentiation from E14 
cortical precursors (our unpublished observations). The molecular mechanisms that may 
explain these differential effects of PACAP on cortical precursors are unknown. 
However, there is evidence for the existence of silencing mechanisms that prevent the 
inappropriate onset of astrocyte differentiation and GFAP expression before 
neurogenesis is completed even in the presence of astrogliogenic signals; and in turn, 
the acquisition of competence to generate astrocytes is accompanied by the coordinate 
inhibition of the neurogenic potential of precursor cells (Fan et al., 2005; Hermanson et 
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al., 2002; Miller and Gautier, 2007; Nieto et al., 2001; Park et al., 1999; Qian et al., 
1997; Song and Ghosh, 2004; Sun et al., 2001; Takizawa et al., 2001; Viti et al., 2003).  
 Our results show that the activation of Ras by PACAP in cortical precursor cells 
requires cAMP, because it can be efficiently blocked by the cAMP antagonist Rp-
cAMPS. Furthermore, the activation of Ras by cAMP is also supported by our 
experiments showing that the transcriptional effects of 8Br-cAMP on the GFAP 
promoter can be significantly reduced by the dominant negative mutant RasN17. It is 
unlikely that the inhibition of Ras activation by Rp-cAMPS is due to inhibition of PKA, 
because inhibition of PKA by H89 does not affect the response to PACAP in terms of 
GFAP promoter stimulation and astrocyte differentiation. Since the cAMP antagonist 
Rp-cAMPS can block the cAMP-dependent activation of small GTPases such as Epac 
in addition to blocking PKA (Rehmann et al., 2003; Van Haastert et al., 1984), it is 
possible that the effect of the cAMP antagonist on the activation of Ras by PACAP 
could be due to direct blockade of a Ras-associated GTPase such as CNrasGEF. This 
GTPase can activate Ras in a PKA-independent manner upon treatment with 8Br-cAMP 
(Amsen et al., 2006; Pham et al., 2000) or in response to elevation of intracellular 
cAMP levels following ligand-dependent stimulation of β1 adrenergic receptors (Pak et 
al., 2002), which are seven transmembrane domain G protein-coupled receptors similar 
to PAC1 receptors for PACAP. 
 The molecular mechanisms by which PACAP and cAMP stimulate transcription 
of the GFAP gene during astrocyte differentiation are unknown. Ongoing studies in our 
laboratory indicate that they may involve changes in the intracellular concentrations of 
calcium ions. In different cell types, activation of Ras or Epac can lead to changes in 
intracellular calcium concentrations (Fitzgerald, 2000; Kang et al., 2003; Ster et al., 
2007). Thus, cAMP production following PACAP activation of PAC1 receptors in 
 15 
cortical precursor cells triggers the stimulation of Rap1- and Ras-dependent intracellular 
signaling cascades that could include changes in the concentrations of calcium ions. 
These changes would lead to stimulation of transcriptional activity of the GFAP gene 
during the process of astrocyte differentiation. 
 
EXPERIMENTAL METHODS 
Reagents. CNTF and bFGF were from PeproTech EC Ltd. (London, England). PACAP-
38, H-89, and 8-Br-cAMP were obtained from Sigma Chemical Co. (Madrid, Spain). 
8CPT-2-O-Me-cAMP was purchased from Biolog Life Science Institute (Bremen, 
Germany). 
 
Plasmids. The luciferase reporter plasmid GFAP-A7Luc bearing a region of the rat 
GFAP gene promoter corresponding to nucleotides -1546 to +13 relative to the 
transcription initiation site has been described in detail in previous studies (Bonni et al., 
1997; Cebolla and Vallejo, 2006; Krohn et al., 1999). The plasmids pGEX-Raf1-RBD 
encoding GST-Raf1-RBD, and those encoding RasN17 and RasV12 were provided by 
Dr. P. Crespo (Universidad de Cantabria, Santander, Spain) and have been described 
(Matallanas et al., 2003). pGEX-RalGSD-RBD encoding GST-RalGSD-RBD and the 
expression vector for Rap1N17 (Vossler et al., 1997) were provided by Dr. L. Cacicedo 
(Hospital Ramon y Cajal, Madrid) with permission from Dr. P.J.S. Stork (Vollum 
Institute, Portland, Oregon).  
 
Cell culture and transfections. Primary cortical cell cultures were prepared from the 
cerebral cortex dissected from fetal brains of E17 Wistar rats as described (Vallejo and 
Vallejo, 2002). Briefly, cell suspensions prepared by trituration of the fetal cortex were 
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washed and resuspended in serum-free DMEM containing N1 supplement (Sigma) and 
1 mM sodium pyruvate (defined medium). Basic FGF (20 ng/ml) was added and cells 
were seeded into 10 cm dishes coated with poly-ornithine, at a density of 2-4 x 104 
cells/cm2. Cells were incubated for expansion at 37 ºC for 3-4 days. Medium was 
replaced every two days. 
 Differentiation experiments were carried out with cells plated into 35 mm dishes 
at a density of 5 x 104 cells/cm2. After incubation at 37 ºC for 24 hours, bFGF-
containing medium was replaced with bFGF-free defined medium, and PACAP (100 
nM), 8CPT-2-O-Me-cAMP (100 µM) or BDNF (50 ng/ml) were immediately added. 
After the addition of these compounds cells were incubated for 2-5 days, at the end of 
which they were processed for immunocytochemistry or immunofluorescence. To 
evaluate the possible involvement of PKA activation during astrocyte differentiation, 
exposure to PACAP was limited to two hours, since we have previously established that 
this period of time is sufficient to trigger differentiation (Vallejo and Vallejo, 2002). 
After this time the medium was replaced and cells were cultured in defined medium 
until harvesting. In this case, H89 (10 µM) was added 15 minutes before PACAP.  
 For transfections, 106 cells/plate were seeded into poly-ornithine-coated 60 mm 
dishes. After an overnight incubation in defined medium in the presence of bFGF (20 
ng/ ml), the medium was removed and 3 µg of reporter plasmid DNA mixed with 10 µl 
FuGENE 6 Transfection Reagent (Roche) were added in 4 ml defined medium and 
incubated for 4 hours. After this, the medium-DNA mix was removed and substituted 
with fresh defined medium, or with defined medium containing different compounds for 
treatments as indicated. In cotransfection experiments, expression vectors were added at 
the indicated amounts, and total DNA amount was kept constant by addition of empty 
vector. Luciferase activity and normalization of values were determined using a 
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commercial assay system (Promega) 48 hours after transfection exactly as described 
(Cebolla and Vallejo, 2006). Transfection of RSV-Luc was used as an independent 
standard for normalization, and efficiencies were corrected by using the Renilla 
luciferase assay system (Promega). All the values are expressed as mean + s.e.m. of at 
least five independent experiments carried out in duplicates. 
 
Western blot. Whole cell extracts from primary cells were prepared and proteins (20 
µg) were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. GFAP 
and β-actin immunoreactivities were detected with specific monoclonal antibodies, 
(clone G-A-5, 1:10,000 dilution; and clone AC-15, 1:10,000 dilution, respectively; 
Sigma) followed by incubation with a horse anti-mouse peroxidase-conjugated 
secondary antibody (1:5,000 dilution) (BioRad, Hercules, CA). Rabbit polyclonal 
primary antisera were used for immunodetection of CREB (Santa Cruz, used at 1:2000 
dilution) and phospho-CREB (Upstate, used at 1:1000 dilution). Incubations with these 
antisera were followed by incubation with a goat anti-rabbit peroxidase-conjugated 
secondary antibody (1:10,000 dilution) (BioRad, Hercules, CA). Immunoreactive bands 
were visualized using an enhanced chemiluminescence detection system (ECL, 
Amersham, Buckinghamshire, England). 
 
Endogenous Rap1 and Ras activation assay. Activated Rap1 (Rap1-GTP) or activated 
Ras (Ras-GTP) were detected using glutathion-S-transferase (GST) pull down assays as 
described (de Rooij and Bos, 1997; Taylor and Shalloway, 1996; Zwartkruis et al., 
1998). Cells were washed twice with ice-cold PBS and then they were incubated at 4 ºC 
for 10 min in 0.5 ml of lysis buffer containing: 25 mM Tris-HCl (pH 7.5), 5 mM EGTA, 
15 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 1% N-octilglucoside, 1 mM 
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phenylmethylsulfonyl fluoride and protease inhibitors (Complete Protease Inhibitor 
Cocktail, Roche). Lysates were clarified by centrifugation at 10,000 g for 10 minutes, 
and 1 mg of total proteins from the supernatants were incubated with glutathione-
sepharose beads (Amersham Biosciences). The beads were freshly coupled to GST-
RalGDS-RBD to isolate Rap1-GTP, or to GST-Raf1-RDB to isolate Ras-GTP. Protein 
complexes were allowed to form for 1 h at 4 ºC, after which the beads were washed 
three times with lysis buffer and resuspended in Laemmli´s sample buffer. Denatured 
proteins were resolved by SDS-PAGE (12%), transferred to nitrocellulose membranes, 
and detected by western immunoblot using an affinity purified rabbit polyclonal anti-
Rap1 antiserum (Santa Cruz Biotechnology; 1:1000 dilution) or a mouse monoclonal 
anti-Ras antiserum (Oncogene Research Products, San Diego, California; 1:1000 
dilution). Immunoreactive bands were visualized by enhanced chemiluminescence 
(ECL, Amersham, Buckinghamshire, England). 
 
Immunocytochemistry and immunofluorescence. DAB immunocytochemistry for 
GFAP was carried out with cells plated into poly-ornithine-coated 35 mm tissue culture 
dishes, using a specific monoclonal antibody (1:500 dilution) (clone G-A-5, Sigma) 
exactly as described (Vallejo and Vallejo, 2002). Immunodetection was carried out 
using immunoperoxidase staining with a Vectastain ABC kit (Vector Laboratories). 
 For immunofluorescence, cells were grown on glass coverslips and fixed. 
Primary antibodies used were anti-GFAP monoclonal antibody (1:500 dilution, Sigma), 
anti-S100β monoclonal antibody (1:500 dilution, Sigma), rabbit polyclonal anti-Nestin 
antiserum (1:4000 dilution ) (McManus et al., 1999), and anti-Tuj1 monoclonal 
antibody (1:500 dilution, Sigma). In the case of double GFAP-S100β 
immunofluorescence, a rabbit polyclonal anti-GFAP antiserum (1:200 dilution, Dako) 
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was used. Secondary antibodies were Alexa-488 or Alexa-546 donkey anti-rabbit or 
donkey anti-mouse (Molecular Probes) used at a 1:500 dilution. Nuclei were 
counterstained with Hoechst 3342 (Invitrogen). Digital images were taken using a Leica 
TCS SP5 confocal microscope, except those corresponding to experiments with BDNF, 
in which case a Nikon 90i microscope equipped with a digital camera was used.  
 
RNA interference. RNA interference was carried out using double stranded RNA 
duplexes transfected into primary cortical cells from the cerebral cortex of E17 Wistar 
rats prepared as described above. Cells (2 x 106 per plate) cultured into 60 mm dishes 
were incubated in 1.5 ml DMEM and transfected by adding a mixture containing 5 µl 
Lipofectamine (Invitrogen), 500 µl OptiMEM (Invitrogen) and small interfering RNA 
(siRNA). After incubation for 6 hours, the medium-siRNA mix was removed and 
substituted with fresh defined medium. Forty eight hours later, cells were treated with 
PACAP (100 nM) or CNFT (30 ng/ml) for another 24 hours, after which GFAP 
expression was assayed by western immunoblot. The sequences of the custom siRNA 
duplexes (StealthTM RNAi system, Invitrogen) used are as follows (only sense strand is 
indicated):  
H-Ras, CCAAGUCCUUUGAAGACAUACAUCA;  
K-Ras, GAAUAAGUGUGACUUGCCUUCUAGA;  
N-Ras, UGGCCAAGAGUUAUGGAAUUCCAUU;  
Rap1a, CAGAAUUUAGCAAGACAGUGGUGUA;  
Rap1b, CAGCCAUGAGAGAUCUGUACAUGAA. 
A commercially available StealthTM RNAi negative control duplex with medium (48%) 
GC content (Invitrogen) was used. Cells were transfected with a mixture of siRNAs for 
the three Ras isoforms, a mixture of siRNAs for the two Rap1 isoforms, or a mixture of 
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siRNAs for all Ras and Rap1 isoforms. Each siRNA duplex was used at a concentration 
of 80 nM. The total concentration of siRNA (400 nM) was kept constant in all 
transfections by adding the negative control siRNA to the mixture as necessary. 
Transfection efficiency was assessed by a fluorescein-labeled siRNA (Invitrogen) and 
estimated to be greater than 90%. 
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FIGURE LEGENDS 
Figure 1. PACAP triggers astrocyte differentiation from cortical precursor cells. (A) 
Control cells growing in the presence of bFGF (20 ng/ml) express the neural precursor 
marker nestin (green) but not the astroglial markers GFAP or S100β, nor the neuronal 
marker Tuj1. Rabbit polyclonal anti-Nestin antiserum was coincubated with either anti-
GFAP, anti-S100β, or anti-Tuj1 monoclonal antibodies. (B) Cells exposed to PACAP 
(100 nM) express the astroglial markers GFAP (red) and S100β (green), but not nestin 
or the neuronal marker Tuj1. A rabbit polyclonal anti-GFAP antiserum was coincubated 
with the anti-S100β monoclonal antibody. (C) Differentiation of neurons from cortical 
precursor cells exposed to BDNF (50 ng/ml). Note that in most cells nestin expression 
(green) is downregulated. Cells showing initiation of neuronal differentiation indicated 
by the presence of Tuj1 (red) do not express nestin. Examples of these young neurons 
are indicated by arrowheads. Cells with more advanced degree of differentiation 
showing dendritic trees typical of fully differentiated neurons are observed. The right 
panel depicts a higher magnification field. Scale bar corresponds to 50 µm. In all cases 
cell nuclei have been counterstained with Hoechst 3342 (blue). 
 
Figure 2. Activation of PKA by PACAP is not involved in stimulation of GFAP 
expression during astrocyte differentiation. (A and B) Relative levels of luciferase 
activity elicited in primary cortical precursor cells transfected with the reporter plasmid 
GFAP-A7Luc. Cells were left untreated (-), or were treated with PACAP (100 nM), 
8Br-AMP (1 mM), H89 (10 µM) or a combination of H89 and PACAP. In this case, 
PACAP was added 15 minutes after the addition of H89. (C) Western immunoblot 
showing phosphorylation of CREB by exposure to PACAP (100 nM) for the indicated 
periods of time (upper panel). A specific anti-phospho-CREB antiserum was used. The 
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use of an antiserum that does not discriminate between CREB and phospho-CREB 
(bottom panel) indicates that the total levels of CREB are not affected by exposure to 
PACAP. (D) Western immunoblot carried out with an anti-phospho-CREB antiserum 
showing inhibition of PACAP-induced CREB phosphorylation in the presence of the 
PKA inhibitor H89 (10 µM). Primary cortical cells were exposed to PACAP (100 nM) 
for 5 minutes, and H89 (10 µM) was added 15 minutes before PACAP. Total CREB 
immunoreactivity was used as a control to monitor even loading of samples. (E) 
Western immunoblot showing expression of GFAP in extracts of primary cortical cells 
treated with PACAP (100 nM), in the absence or presence of H89 (10 µM) administered 
15 minutes earlier. Cells were exposed to PACAP for two hours and were harvested two 
days after the onset of treatment. Actin immunoreactivity was used as a control to 
monitor even loading of samples. (F) Immunocytochemical staining of GFAP in 
primary cortical cells treated with PACAP (100 nM), in the absence or presence of H89 
(10 µM) administered 15 minutes earlier. Cells were exposed to PACAP for two hours 
and were processed for immunocytochemistry two days after the onset of treatment. 
Note that the presence of the PKA inhibitor H89 does not prevent GFAP expression (E) 
or astrocyte differentiation (F). 
 
Figure 3. Involvement of the activation of Rap1 in PACAP-induced stimulation of the 
GFAP promoter. (A) GST pull down assay showing activation of Rap1 (Rap1-GTP) in 
response to treatment of primary cortical precursor cells either with PACAP (100 nM) 
for the indicated periods of time (minutes), or with the cAMP analog 8CPT-2-O-Me- 
cAMP (8CPT-cAMP), a specific agonist for the activation of Epac. Cells were exposed 
to 8CPT-2-O-Me-cAMP (100 µM) for 15 minutes. (B) Relative luciferase activities 
elicited in primary cortical precursor cells cotransfected with the reporter plasmid 
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GFAP-A7Luc and with the indicated amounts (µg) of an expression vector encoding 
Rap1N17, a dominant negative mutant of Rap1. Cells were left untreated (white 
columns), or treated (black columns) with PACAP (100 nM). *p<0.01 relative to values 
obtained in PACAP-treated cells in the absence of Rap1N17 (Student’s t-test). (C) A 
similar experiment to the one indicated in (B), but treating cells with CNTF (30 ng/ml) 
instead of PACAP. 
 
Figure 4. Stimulation of Epac is not sufficient to induce GFAP gene expression during 
astrocyte differentiation. (A) Relative levels of luciferase activity elicited in primary 
cortical precursor cells transfected with the reporter plasmid GFAP-A7Luc. Cells were 
left untreated (-), or were treated with PACAP (100 nM), 8Br-cAMP (1 mM), or 8CPT-
2-O-Me-cAMP (8CPT-cAMP, 10 or 100 µM). (B) Western immunoblots carried out 
with extracts of primary cortical precursor cells showing induction of GFAP expression 
in cells treated with PACAP (100 nM) or 8Br-cAMP (1 mM), but not in those treated 
with 8CPT-2-O-Me-cAMP (8CPT-cAMP, 100 µM). (C) Immunocytochemical staining 
of GFAP in primary cortical precursor cells induced to differentiate to astrocytes by 
treatment with PACAP (100 nM). Note that astrocyte differentiation was not induced in 
cells treated with 8CPT-2-O-Me-cAMP (8CPT-cAMP, 100 µM).  
 
Figure 5. Involvement of the activation of Ras in PACAP-induced stimulation of the 
GFAP promoter. (A) GST pull down assay showing activation of Ras (Ras-GTP) in 
response to treatment of primary cortical precursor cells with PACAP (100 nM) for the 
indicated periods of time. (B) Relative luciferase activities elicited in primary cortical 
precursor cells cotransfected with the reporter plasmid GFAP-A7Luc and with the 
indicated amounts (µg) of an expression vector encoding RasN17, a dominant negative 
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mutant of Ras. Cells were left untreated (white columns), or were treated (black 
columns) with PACAP (100 nM). *p=0.024 and **p<0.02, relative to values obtained in 
PACAP-treated cells in the absence of RasN17 (Student’s t-test). (C) A similar 
experiment to the one indicated in (B), but treating cells with CNTF (30 ng/ml) instead 
of PACAP. (D) Relative luciferase activities elicited in primary cortical precursor cells 
cotransfected with the reporter plasmid GFAP-A7Luc and with the indicated amounts 
(µg) of an expression vector encoding RasV12, a constitutively active mutant of Ras. 
For comparison, the luciferase activity of cells transfected only with GFAP-A7Luc and 
treated with PACAP (100 nM) is shown. 
 
Figure 6. Involvement of cAMP on the PACAP-induced activation of Ras. (A) GST 
pull down assay showing activation of Ras (Ras-GTP) in response to treatment of 
primary cortical precursor cells with PACAP (100 nM) for 5 minutes. Note that PACAP 
failed to activate Ras in the presence of the cAMP antagonist Rp-cAMPS (10 µM), 
which was administered 10 minutes before PACAP. (B) Relative luciferase activities 
elicited in primary cortical precursor cells cotransfected with the reporter plasmid 
GFAP-A7Luc and with the indicated amounts (µg) of an expression vector encoding 
RasN17, a dominant negative mutant of Ras. Cells were left untreated (white columns), 
or were treated (black columns) with the cAMP analog 8Br-cAMP (1 mM). *p<0.005 
relative to values obtained in 8Br-cAMP-treated cells in the absence of RasN17 
(Student’s t-test) 
 
Figure 7. (A) Relative luciferase activities elicited in primary cortical precursor cells 
cotransfected with the reporter plasmid GFAP-A7Luc and with expression vectors 
encoding Rap1N17 (1 µg) or RasN17 (0.5 µg). Cells were left untreated (white 
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columns), or were treated (black columns) with the PACAP (100 nM). Note that when 
both dominant negative inhibitors are present at the same time the effect of PACAP on 
the GFAP promoter activity is almost completely inhibited. (B) A similar experiment to 
the one indicated in (B), but treating cells with CNTF (30 ng/ml) instead of PACAP. 
(C) Western immunoblot showing endogenous GFAP expression in cells transfected 
with siRNA for Rap1 and Ras as indicated on top. Note that the presence of siRNA for 
both Rap1 and Ras at the same time specifically prevents stimulation of GFAP 
expression by PACAP but not by CNTF. Actin immunoreactivity was used as a control 
to monitor even loading of samples. (D) Relative luciferase activities elicited in primary 
cortical precursor cells cotransfected with the reporter plasmid GFAP-A7Luc and with 
the indicated amounts (µg) of an expression vector encoding RasV12. Some cells were 
treated with 8CPT-2-O-Me-cAMP (8CPT-cAMP, 100 µM). For comparison, the first 
two bars to the left depict the increase in luciferase activity observed in cells transfected 
only with GFAP-A7Luc and treated with PACAP (100 nM). *p<0.05, relative to values 
obtained in 8CPT-2-O-Me-cAMP-treated cells in the absence of RasV12 (Student’s t-
test). 
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